Predictors of an adverse 30-day outcome
| OR (95% CI) | p-value | |
| Comorbidities | ||
| Malignant tumour | 1.61 (0.43–6.00) | 0.478 |
| Chronic cardiopulmonary disease | 1.70 (0.60–4.84) | 0.321 |
| Diabetes mellitus | 3.26 (1.10–9.62) | 0.033 |
| Renal insufficiency | 2.48 (0.87–7.10) | 0.091 |
| Symptoms and clinical status on admission | ||
| Syncope | 1.93 (0.51–7.25) | 0.330 |
| Hypoxia | 3.85 (1.28–11.60) | 0.017 |
| Tachycardia | 3.76 (1.29–10.95) | 0.015 |
| Mild hypotension | 2.08 (0.43–9.99) | 0.360 |
| RV dysfunction on echocardiography or MDCT | 2.91 (0.90–9.38) | 0.074 |
| Laboratory biomarkers | ||
| hsTnT ≥14 pg·mL−1 | OR not calculable | |
| NT-proBNP ≥600 pg·mL−1 | OR not calculable | |
| Copeptin ≥24 pmol·L−1 | 5.44 (1.68–17.58) | 0.005 |
| Copeptin ≥24 pmol·L−1 and hsTnT ≥14 pg·mL−1 and NT-proBNP ≥600 pg·mL−1 | 13.00 (3.91–42.72) | <0.001 |
| Risk assessment models | ||
| ESC 2014 algorithm (intermediate–high risk versus low risk/intermediate–low risk) | 4.66 (1.54–14.09) | 0.006 |
| Bova score (intermediate–high risk versus low risk/intermediate–low risk) | 2.73 (0.89–8.42) | 0.080 |
Definitions are provided in the material and methods section of the online supplementary material. RV: right ventricular; MDCT: multidetector computed tomography; hsTnT: high-sensitivity troponin T; NT-proBNP: N-terminal pro-brain natriuretic peptide; ESC: European Society of Cardiology.